iPSC Biobank of Biomarkers Diversity in Cardiovascular Disease

Status Recruiting

Clinical Trial Summary

The Investigators will create a clinical database and a Biobank of stem cells derived from the blood of participants with cardiovascular disease. The Investigators will recruit participants from diverse racial and ethnic backgrounds with equal representation from both sexes. The Investigators expect to create stem cells and analyze the blood for protein biomarkers and genetic causes of cardiovascular disease. The stem cell biobank and clinical data will be a powerful tool for studying cardiovascular disease.

Clinical Trial Description

Cardiovascular disease is the leading cause of morbidity and mortality. The development of cardiovascular disease includes both genetic and epigenetic factors. Understanding their molecular and cellular mechanism is necessary to identify novel drug targets and treat the disease. Present in vitro and in vivo models of the disease do not mimic human pathophysiology, and obtaining the primary cells from the patients for the studies relevant to the cardiovascular and pulmonary system is difficult. Induced pluripotent stem cells (iPSCs) are derived from a person's blood cells and facilitate the discovery of cardiovascular disease mechanisms. The Investigators propose recruiting cardiovascular patients from diverse ethnic backgrounds and creating a rich clinical database using REDCap. Blood samples will be obtained from participants and used to create iPSCs. The participant will have DNA sequencing, and serum will be analyzed for protein biomarkers. The multi-omics data and reprogrammed iPSCs will be stored in the Cardiology and Critical Care (C3RP) laboratory at the Robarts Research Institute at Western University. The reprogrammed iPSCs can generate a limitless supply of cardiovascular tissue. Moreover, the iPSC-derived data will be correlated with clinical information, genetic sequencing, and protein biomarkers from serum analysis. The Investigators expect to create an iPSC biobank coupled with a rich clinical dataset, including genetic sequencing analysis and protein biomarkers that will enable the discovery of novel biomarkers and drug targets for cardiovascular disease. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06371937
Study type	Observational [Patient Registry]
Source	Lawson Health Research Institute
Contact
Status	Recruiting
Phase
Start date	May 1, 2024
Completion date	June 30, 2033

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05196659` - Collaborative Quality Improvement (C-QIP) Study	N/A
Recruiting	`NCT05650307` - CV Imaging of Metabolic Interventions
Recruiting	`NCT05654272` - Development of CIRC Technologies
Active, not recruiting	`NCT05896904` - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction	N/A
Completed	`NCT05077293` - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting	`NCT05631275` - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation	`NCT05564572` - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology	N/A
Enrolling by invitation	`NCT05009706` - Self-care in Older Frail Persons With Heart Failure Intervention	N/A
Recruiting	`NCT04177199` - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated	`NCT03615469` - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)	N/A
Recruiting	`NCT06340048` - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure	Phase 1/Phase 2
Recruiting	`NCT05679713` - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed	`NCT04254328` - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure	N/A
Completed	`NCT03549169` - Decision Making for the Management the Symptoms in Adults of Heart Failure	N/A
Recruiting	`NCT05572814` - Transform: Teaching, Technology, and Teams	N/A
Enrolling by invitation	`NCT05538611` - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting	`NCT04262830` - Cancer Therapy Effects on the Heart
Completed	`NCT06026683` - Conduction System Stimulation to Avoid Left Ventricle Dysfunction	N/A
Withdrawn	`NCT03091998` - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support	Phase 1
Recruiting	`NCT05564689` - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

iPSC Biobank of Biomarkers Diversity in Cardiovascular Disease — INFERENCE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms